Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Data on vaccines discussed by F.A. Neethling and colleagues
August 6th, 2008
New investigation results, 'Assessing vaccine potency using TCRmimic antibodies,' are detailed in a study published in Vaccine. "Dendritic cells (DCs) are highly specialized antigen-presenting cells of the immune system that are efficient at presenting peptide-antigen for the activation of T cells and are often the cell type of choice for vaccine targeting by virtue of high expression levels of MHC and costimulatory molecules. Since the level of peptide-MHC complex significantly influences stimulation of T cells, a proof-of-concept potency assay was developed to directly examine the presentation and density of MHC class I peptides derived from the processing of a model tumor...
Source: Vaccine Weekly (2008-08-06)
|
|
Advertisement |
|
|
|
